Cite

    Wetmore, J. et al. (2021). Risk of hyperkalemia from renin–angiotensin–aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrology dialysis transplantation. 36 (5), pp. 826-839. [Online].